CEO, Inserm Transfert
Dr. Tharaud joined Inserm in 2005 with a mission to reorganise technology transfer activities. In 2006 she was appointed CEO of Inserm Transfert, Inserm's private affiliate dedicated to all knowledge transfer activities.
Dr. Tharaud previously had a ten-year career in the pharmaceutical and biotechnology industries.
In 1993 she joined the French affiliate of Glaxo (now GlaxoSmithKline) as a Manager of New Product Strategy, before moving to the French affiliate of SmithKline Beecham in 1995 as Manager of Business Development. At SmithKline Beecham, Dr. Tharaud developed the business development function in France and actively evaluated product and technology licensing opportunities.
In 1996, Dr. Tharaud joined Genset, a listed genomics company, as Director of Patents and Licensing. She was responsible for designing and executing the Company's intellectual property strategy. In 1999, Dr. Tharaud became Vice President, Operations. In 2001, Dr. Tharaud joined the transatlantic functional genomics company Valigen as Chief Operating Officer. At Valigen, Dr. Tharaud managed the integration of the 3-way merger that created this 170-employee company.
From 2002 to 2004, Dr Tharaud run interim management positions for biotech companies, as well as consulting missions for venture capital firms. She worked for Biosciences Managers Ltd.
Dr. Tharaud received an MBA from INSEAD, a PhD in molecular genetics and immunology from the Institut National Agronomique, and an MSc from the Ecole Polytechnique. Dr. Tharaud has also completed an advanced education course at the Centre of the Advanced Study and Research on Intellectual Property at the law school of the University of Washington, Seattle, USA.